A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Tasquinimod (Primary)
  • Indications Prostate cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Ipsen Pharmaceuticals
  • Most Recent Events

    • 20 Oct 2017 Results assessing clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy, were published in the Annals of Oncology.
    • 16 Apr 2015 After an interim analysis of the phase III 10TASQ10 study showed that tasquinimod did not improve overall survival, and efficacy results together with preliminary safety data did not support a positive benefit-risk balance in this population, Active Biotech and Ipsen announced their decision to discontinue the development of tasquinimod in prostate cancer, according to a media release.
    • 16 Apr 2015 Status changed from active, no longer recruiting to discontinued, according to a media release from Active Biotech and Ipsen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top